- FDA Will Begin to Regulate Thousands of Lab Tests
- Want a Healthy Old Age? Get Your Finances in Order Now
- COVID Triggered More Cases of Deadly Sepsis During Pandemic Than Thought
- Biden Administration Says Insurance Issues With COVID Shots Mostly Fixed
- Jimmy Carter ‘Happy’ in At-Home Hospice Care as 99th Birthday Nears
- Getting COVID Shot During Pregnancy Helps Protect Newborns, CDC Study Finds
- Most Older Americans Object to Cancer Screening Cutoffs Based on Life Expectancy: Poll
- Childbirth Can Leave New Parents in Serious Medical Debt
- Brains of Patients With Post-Op Delirium Could Be More Vulnerable
- Kids With Eczema May Need Further Allergy Tests
FDA Approves Antibiotic for Skin Infections

The U.S. Food and Drug Administration has approved the intravenous antibiotic Dalvance (dalbavancin) to treat methicillin-resistant Staphylococcus aureus (MRSA) and other potentially deadly bacterial skin infections resistant to older antibiotics.
Dalvance was given priority review and designated a “Qualified Infectious Disease Product” since it’s meant to treat serious bacterial or fungal infections, the FDA said in a news release.
The drug’s safety and effectiveness were evaluated in clinical studies involving nearly 1,300 people with acute bacterial skin infections. The most common side effects were nausea, headache and diarrhea. Study participants who took Dalvance also showed a higher-than-expected incidence of elevated liver enzymes in one screening test, the agency said.
Dalvance is marketed by Durata Therapeutics of Chicago.
More information
The FDA has more about this approval.
Source: HealthDay
Copyright © 2023 HealthDay. All rights reserved.